UNITED STATES PATENT AND TRADEMARK OFFICE

Trademark Electronic Search System(Tess)

TESS was last updated on Fri Feb 27 04:21:22 EST 2004

View Search History:

WARNING: AFTER **SEARCHING** THE USPTO DATABASE, EVEN IF **YOU** THINK THE RESULTS ARE "O.K.," DO **NOT** ASSUME THAT YOUR MARK CAN BE REGISTERED AT THE USPTO. AFTER YOU FILE AN APPLICATION, THE USPTO MUST DO ITS OWN SEARCH AND OTHER REVIEW, AND MIGHT **REFUSE TO REGISTER** YOUR MARK.

◉ Plural and Singular ○ Singular

◉ Both ○ Live ○ Dead

Search Term: RITUXIMAB

Field: Combined Word Mark (BI,TI,MP,TL)

Result Must Contain: All Search Terms (AND)

Submit Query | Clear Query

Logout *Please logout when you are done to release system resources allocated for you.*

This ***New User (Basic)*** search form allows for searching of the most commonly searched fields: word marks, serial or registration numbers, and owners.

The **Combined Word Mark** is the default search field and includes the **word mark** and **translation**.

Use the **$** for truncation in any field. For **Combined Word Mark** searches, the * is a more efficient truncation operator for left and/or right truncation. For example, the search term ***DOG*** with the **Combined Word Mark** will retrieve marks with common variations of the word DOG in the word mark or translation statements. Use of the $ truncation operator sometimes results in a truncated hit list.

For serial number or registration number searches, enter the 8-digit serial number (e.g. 75123456) or 7-digit registration number (e.g., 1234567) and select ***Serial or Registration Number*** as the *Field* for the search. If multiple serial or registration numbers are searched, separate the numbers by spaces and change the *Results Must Contain* value to Any Search Terms (OR). (Alternatively, separate the number by the Boolean OR operator without adjusting the *Result Must Contain* value.)

Do **NOT** include the apostrophe for contractions. For example, search for the word **DON'T** by searching **DON T**. Including Boolean operators (e.g., AND, OR, NOT) or proximity operators (e.g., ADJ, NEAR, SAME, WITH) in your search will override the *Result Must Contain* setting for the search. To actually search for these Boolean or proximity operators, include quotes around the operator.

TRADEMARK

Sorry, No results were found for your query.

Click on the Back button in your browser

Logout

Please logout when you are done to release system resources allocated for you.

```
      ---  -----  -----------
? s rituximab
      S1      36  RITUXIMAB
? s atcc
      S2   10152  ATCC
? s s1 and s2
             36  S1
          10152  S2
      S3       2  S1 AND S2
? t s3/3,k,ab/1-2

 3/3,K,AB/1
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2004 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10069121  IFI Acc No: 2002-0012665  IFI Acc No: 2002-0003424
Document Type: C
COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR
TREATMENT OF B CELL LYMPHOMA; ADMINISTERING AN ANTI-CYTOKINE ANTIBODY OR
FRAGMENT THEREOF OR CYTOKINE ANTAGONIST TO A PATIENT DIAGNOSED WITH A
HEMATOLOGIC MALIGNANCY OR A SOLID, NON-HEMATOLOGIC TUMOR PRIOR, CONCURRENT
OR AFTER ADMINISTRATION CHEMOTHERAPEUTIC AGENT
Inventors: Hanna Nabil (US)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000
Publication (No,Date), Applic (No,Date):
US 20020012665 20020131 US 2001822672  20010402
Publication Kind:  A1
Priority Applic(No,Date): US 2001822672  20010402
Provisional Applic(No,Date): US 60-193467   20000331

Abstract: The present invention discloses combined therapies for treating
hematologic malignancies, including B cell lymphomas and leukemias or solid
non-hematologic tumors, comprising administration of anti-cytokine
antibodies or antagonists to inhibit the activity of cytokines which play a
role in perpetuating the activation of B cells. The administration of such
antibodies and antagonists, particularly anti-IL10 antibodies and
antagonists, is particularly useful for avoiding or decreasing the
resistance of hematologic malignant cells or solid tumor cells to
chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The
invention  also provides combination therapies for solid tumors having B
cell involvement comprising the administration of an anti-cytokine antibody
and a  B cell depleting antibody such as RITUXAN registered .


Non-exemplary Claims: ...41. The method of claim 40, where said chimeric
   anti-CD20 antibody is Rituximab registered42. The method of claim
   41, wherein said Rituximab registered is administered at a dosage
   of 0.4 to 20 mg/kg body weight...wherein said anti-CD20 antibody is
   Rituxan registered , a chimeric anti-CD20 antibody produced by
   ATCC 69119....71. The method of claim 70 wherein said antibody is
   Rituxan registered produced by ATCC 69119...


 3/3,K,AB/2
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2004 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3887549  IFI Acc No: 0020642
Document Type: C
METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(I)
ANTIBODIES; CLASSIC COMPLEMENT PATHWAY, C3 CONVERTASE
Inventors: Chung Leland (US); Nardin Alessandra (FR); Sokoloff Mitchell H
    (US); Sutherland William M (US); Taylor Ronald (US)
```

Assignee: Virginia, University of Alumni Patents Foundation
Assignee Code: 22061
Publication (No,Date), Applic (No,Date):
US 6572856 20030603 US 2000724620 20001128
Publication Kind: B
Cont.-in-part Pub(No),Applic(No,Date): US 88392500 19880209
Priority Applic(No,Date): US 2000724620 20001128; US 88392500 19880209

Abstract: The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/ or complement components in combination with antibodies specific for C3b(i). The present invention also relates methods of treating and preventing cancer, viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more cancer cell antigens, viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.

Non-exemplary Claims: ...of the anti-C3b(i) antibodies is 3E7 produced by the hybridoma deposited with the **ATCC** as Accession No. PTA-4090...

...wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the **ATCC** as Accession No. PTA-4090...

...41. The method of claim 24, wherein the anti-CD20 antibody is **rituximab**.
...

...wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the **ATCC** as Accession No. PTA-4090 and the anti-CD20 antibody is **rituximab**.
?

U.S. Application No. 09/762,587
Attorney Ref. No. 037003-0277847

Examiner Davis:

Pages 2-3 of our previous facsimile correspondence (the Bexxar product insert) can be found at:

http://www.corixa.com/Bexxar/BexxarPackageInsert.pdf

The complete citation for the Coleman et al. meeting abstract is as follows:

Coleman M, Kaminski MS, Knox SJ, Zelenetz AD, et al. The BEXXAR Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab) Produced Durable Complete Remissions in Heavily Pretreated Patients with Non-Hodgkin's Lymphoma (NHL), Rituximab-Relapsed/Refractory Disease, and Rituximab-Naive Disease. Proc Am Soc Hem. *Blood.* 2003; 102(11):29a, Abstract #89.

The abstract was presented as an oral session at the 45th annual meeting of the American Society of Hematology on December 7, 2003.

Julie Brancheau Meiza